Q4 Inc. Receives Support from Independent Proxy Advisor ISS and Issues Materials Detailing Why Shareholders Should Vote FOR the Value-Maximizing Proposed Acquisition by Sumeru Equity Partners
Q4 Inc. (TSX:QFOR) (“Q4” or the “Company”), the leading capital markets access platform, today sent a letter to shareholders and issued a presentation highlighting reasons to support the proposed arrangement transaction (the “Arrangement”) whereby Q4 would be acquired by a newly formed entity controlled by Sumeru Equity Partners (“Sumeru”), a leading technology-focused investment firm. A special meeting (the “Special Meeting”) of holders (the “Shareholders”) of the Company’s common shares (the “Common Shares”) related to the proposed Arrangement will be held on January 24, 2024 at 10:00 a.m. (Toronto Time).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240110462013/en/
The presentation is available on the Company’s website at https://investors.q4inc.com/Special-Meeting-Vote/Special-Meeting/.
Further, Q4 announced that a leading proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”), has recommended Shareholders vote “FOR” the transaction, citing as reasons for its conclusion the “significant premium,” “reasonable” sale process, and “credible downside risk” if the Arrangement is not approved.
The full text of the letter follows:
Reminder to Vote Today.
Deadline to Submit Your Proxy Vote is January 22, 2024 at 10 a.m. (Toronto Time).
Dear Shareholders,
Thank you for your investment in Q4 Inc. (TSX:QFOR) (“Q4” or the “Company”).
As part of our ongoing commitment to delivering value to you, we recently agreed to a proposed Arrangement (the “Arrangement”) whereby Q4 would be acquired by a newly formed entity controlled by Sumeru Equity Partners (“Sumeru”), a leading technology-focused investment firm.
Under the terms of the proposed Arrangement, Shareholders – other than certain Shareholders rolling over their equity interest (“Rolling Shareholders”) – would receive an all-cash payment of C$6.05 per share, representing a 36% premium to the closing price of the Company’s Common Shares on November 10, 2023, the last trading day prior to the Arrangement being announced.
The Arrangement, if approved, will provide Shareholders with immediate, significant, and certain value following a robust strategic review process overseen by an independent Special Committee (“Special Committee”) of the Board of Directors.
The Board (other than conflicted directors) unanimously recommends that you vote “FOR” the proposed Arrangement at the Special Meeting of Shareholders (“Special Meeting”) to be held on January 24, 2024, at 10 a.m. (Toronto Time). The Special Meeting will be held virtually via live audio webcast at: https://meetnow.global/MA5VC62.
Why the Arrangement is the Best Path Forward
We believe that the rationale for the Arrangement is clear and that it represents the optimal pathway for Shareholders. Selected reasons for this include:
-
Premium Consideration: The Consideration to be received by Shareholders (other than the Rolling Shareholders) represents a 36% premium to the closing price of Q4’s Common Shares as of November 10, 2023, the last day of trading before the Arrangement was announced. The purchase price is a 43% premium to the 20-day volume-weighted average trading price and a 46% premium to the 60-day volume-weighted average prior to the announcement.
-
Certainty of Value and Liquidity: The Consideration offered to Shareholders (other than the Rolling Shareholders) is all cash, which provides immediate liquidity, value realization and certainty for their entire investment.
-
Highest Proposal: The Special Committee concluded after extensive negotiations with Sumeru that the Consideration, which represents an increase from Sumeru’s original proposal, was the highest price that could be obtained from Sumeru and that further negotiation could potentially have caused Sumeru to withdraw its proposal, denying Shareholders the right to vote on the proposed Arrangement.
-
Go-Shop Provision: The Company undertook a Go-Shop process to solicit alternative proposals and was in contact with 23 different parties. None of these discussions resulted in an alternative proposal being presented.
-
Independent Formal Valuation and Fairness Opinions: Stifel Nicolaus Canada Inc. (“Stifel Canada”) provided an independent formal valuation that concluded that as of November 12, 2023, the fair market value of the Company’s Common Shares was in the range of C$5.50 to C$6.80 per Share. Both Stifel Canada and Raymond James & Associates concluded that the Consideration to be received by the Shareholders (other than the Rolling Shareholders) pursuant to the Arrangement was fair from a financial point of view to these Shareholders.
- Minority Vote and Court Approval: The Arrangement must be approved by not only two-thirds of the votes cast by Shareholders, but also by a majority of the minority Shareholders in accordance with applicable securities laws, and by the Ontario Superior Court of Justice (Commercial List), which will consider the fairness and reasonableness of the Arrangement to all Shareholders.
Third Party Support for the Transaction
Don’t just take our word for it. Notably, the reactions from objective parties have reinforced the merits of the transaction.
Leading proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) recently recommended shareholders vote FOR the Arrangement, stating:1
- “The offer represents a significant premium to the unaffected price and the valuation appears credible.”
- “The sale process was ultimately conducted on a comparable basis to other recent notable Canadian software transactions and helped facilitate price discovery.”
- “Based on the company's operational and share price history as well as, at minimum, some expected reversion in share price in the event of non-approval, the standalone case is not an inherently safe path.”
- “On balance, shareholder support for this proposal is warranted.”
Members of the sell side analyst community have also been in favor of the Arrangement:
- “We believe the acquisition is attractive and provides certainty to shareholders.” — RBC Capital Markets, November 13, 2023
- “We consider the announcement a positive outcome for the broader shareholder base, given the headwinds to QFOR’s growth profile as it transitions to breakeven profitability.” — Canaccord Genuity, November 13, 2023
- “We believe the current deal price is reasonable.” — Eight Capital, November 14, 2023
Shareholders are urged to read the Circular and its appendices carefully and in its entirety as the Circular contains extensive detail regarding the background to the Arrangement, detailed reasons for the recommendation of the Special Committee and the Board (including the above reasons) and other factors considered.
After careful consideration of all these factors, including the recommendations of the Company’s financial advisors and the unanimous recommendation of the Special Committee, the Board (with conflicted directors not in attendance or participating in the decision) unanimously determined the Arrangement is the best interests of the Company and is fair to Shareholders (other than the Rolling Shareholders).
As such, we strongly encourage you to vote “FOR” the proposed Arrangement.
Thank you for your continued support of Q4.
Sincerely,
The Special Committee of the Board of Directors of Q4
Due to the Essence of Time, Shareholders are encouraged to vote online or by telephone as describe in the enclosed voting form and on Q4’s website at: https://investors.q4inc.com/Special-Meeting .
The proxy voting deadline is on January 22, 2024 at 10 a.m. Toronto Time.
Shareholder Questions and Assistance
Shareholders who have questions regarding the Arrangement or require assistance with voting may contact Laurel Hill Advisory Group, the Company’s shareholder communications advisor and proxy solicitation agent at:
Laurel Hill Advisory Group
North American Toll Free: 1-877-452-7184 (+1 416-304-0211 Outside North America)
Email: assistance@laurelhill.com.
About Q4 Inc.
Q4 Inc. (TSX: QFOR) is the leading capital markets access platform that is transforming how issuers, investors, and the sell-side efficiently connect, communicate, and engage with each other.
The Q4 Platform facilitates interactions across the capital markets through IR website products, virtual events solutions, engagement analytics, investor relations CRM, shareholder and market analysis, surveillance, and ESG tools. The Q4 Platform is the only holistic capital markets access platform that digitally drives connections, analyzes impact, and targets the right engagement to help public companies work faster and smarter.
The company is a trusted partner to more than 2,500 public companies globally, including many of the most respected brands in the world, and maintains an award-winning culture where team members grow and thrive.
Q4 is headquartered in Toronto, with offices in New York and London. Learn more at investors.Q4inc.com.
All dollar figures in this release are in Canadian dollars unless otherwise indicated.
About Sumeru Equity Partners
Sumeru Equity Partners provides growth capital at the intersection of people and innovative technology. Sumeru seeks to embolden innovative founders and management teams with capital and scaling partnership. Sumeru has invested over US$3 billion in more than fifty platform and add-on investments across enterprise and vertical SaaS, data analytics, education technology, infrastructure software and cybersecurity. The firm typically invests in companies throughout North America and Europe. For more information, please visit sumeruequity.com.
Cautionary Note Regarding Forward-Looking Information
This release includes “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements with respect to the purchase by the Purchaser of all of the issued and outstanding Common Shares, the rationale of the Board for entering into the Arrangement Agreement, the anticipated timing and the various steps to be completed in connection with the Arrangement, including receipt of Shareholder and court approvals, the anticipated timing for closing of the Arrangement.
In some cases, but not necessarily in all cases, forward-looking statements can be identified by the use of forward-looking terminology such as “plans” “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking statements. Forward-looking statements are not historical facts, nor guarantees or assurances of future performance but instead represent management’s current beliefs, expectations, estimates and projections regarding future events and operating performance. Forward-looking statements are necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this release, are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ, possibly materially, from those indicated by the forward-looking statements include, but are not limited to, the possibility that the proposed Arrangement will not be completed on the terms and conditions, or on the timing, currently contemplated, or at all, the possibility of the Arrangement Agreement being terminated in certain circumstances, the ability of the Board to consider and approve a Superior Proposal for the Company, and the other risk factors identified under “Risk Factors” in the Company’s latest annual information form and management’s discussion and analysis for the year ended December 31, 2022 and in the management’s discussion and analysis for the period ended September 30, 2023, and in other periodic filings that the Company has made and may make in the future with the securities commissions or similar regulatory authorities in Canada, all of which are available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors are not intended to represent a complete list of the factors that could affect the Company. However, such risk factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release.
Although the Company has attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other risk factors not currently known to us or that we currently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking statements. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, you should not place undue reliance on forward-looking statements. The forward-looking statements represent the Company’s expectations as of the date of this release (or as the date it is otherwise stated to be made) and are subject to change after such date. However, the Company disclaims any intention and undertakes no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable Canadian securities laws. All of the forward-looking statements contained in this release are expressly qualified by the foregoing cautionary statements.
1 Permission to quote ISS was neither sought nor obtained.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240110462013/en/
Contact information
Investor
Laurel Hill Advisory Group
North America Toll Free: 1-877-452-7184
Collect Calls Outside North America: 1-416-304-0211
assistance@laurelhill.com
Edward Miller
Director, Investor Relations
(437) 291-1554
ir@q4inc.com
Media
Longacre Square Partners
Scott Deveau
sdeveau@longacresquare.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 23:30:00 EEST | Press release
CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved o
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 23:05:00 EEST | Press release
IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global freight industry. “Einride shares our belief that quantum computing will fundamentally reshape and improve how large industries such as transportation and logistics operate,” said Niccolo de Masi, CEO of IonQ. “This partnership is aimed at creating a powerful platform with u
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 22:26:00 EEST | Press release
CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 22:24:00 EEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 22:08:00 EEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom